Skip to main content

Table 2 Toxicities in Level 0 cohort

From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Toxicity G1, % G2, % G3, % G4, %
Hematologic     
 Neutropenia 0 0 11 89
 Leukopenia 0 11 56 33
 Anemia 56 22 0 0
 Thrombocytopenia 56 11 0 0
Nonhematologic     
 AST increased 33 0 11 0
 ALT increased 33 0 11 0
 Anorexia 11 33 22 0
 Stomatitis 11 22 11 0
 Nausea 11 33 0 0
 Diarrhea 22 22 0 0
 Vomiting 22 11 0 0
 Allergic reaction 22 11 0 0
 Hypertension 0 11 0 0
 Dyspnea 0 11 0 0
 Peripheral neuropathy 44 0 0 0
 Constipation 33 0 0 0
 Edema limbs 22 0 0 0
 Weight loss 11 0 0 0
 Febrile neutropenia - - 11 0
 Infection 0 0 11 0
 Sepsis - - - 22
 Hypoxia - 0 11 0
  1. ALT: Alanine aminotransferase, AST: aspartate aminotransferase, G: Grade (according to the National Cancer Institute’s Common Toxicity Criteria for Adverse Events, version 4.0)